November 26, 2025
Shots fired over shots for life
There may not be a safe off-ramp for some taking GLP-1 drugs, study suggests
Commenters clash: forever shots vs “bad headline” club
TLDR: A study found most people who quit GLP-1 weight-loss injections regained weight and lost health gains. Comments split between “it’s a forever med” and “the headline oversells it,” with some pointing out many did keep some weight off—making this a fight over facts and expectations.
A new analysis says people who stop GLP-1 drugs—popular injections like Ozempic and Zepbound that curb appetite—often gain weight back and lose heart health wins, with 82% rebounding after quitting. An editorial even suggests rebranding them as “weight management,” meaning you might be on them indefinitely. Cue the comment war. In the Ars thread, one camp is blunt: it’s a lifetime subscription, like a gym membership you actually use. Mistletoe’s scorching take: “There doesn’t need to be an off-ramp—they just have to take it for life.” Another camp cries headline hype. tyleo argues the phrase “no safe off-ramp” is misleading—this isn’t testosterone therapy where your body stops making the hormone; you can stop, you just might slide back. bryanlarsen brings receipts: “20% kept the weight off and 40% kept half” after stopping, so where’s the “no off-ramp”? Meanwhile, elevation says the post-quit symptoms read like classic yo-yo dieting: cut calories, then rush back to junk food, and surprise—numbers go up. petercooper drops the voice-of-reason: treat it case-by-case and don’t romanticize the meds. The meme-ification is real: commenters joke GLP-1s are the “subscription plan for your pancreas,” with debates over whether that’s scary or just realistic. Full study via JAMA Internal Medicine
Key Points
- •A JAMA Internal Medicine analysis found most people stopping tirzepatide regained weight and lost cardiometabolic benefits.
- •After withdrawal, blood pressure, cholesterol, hemoglobin A1c, and fasting insulin increased toward baseline.
- •An editorial by University of Pittsburgh clinicians suggests reframing GLP-1 drugs as long-term “weight management” therapies.
- •The trial included 670 adults with obesity/overweight (no diabetes), treated for 36 weeks, then randomized for 52 weeks to continue or switch to placebo.
- •Both groups were advised to maintain reduced-calorie diet and exercise; the discontinuation group showed broad regression after stopping.